Wedbush Has Bearish Estimate for Ardelyx FY2026 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at Wedbush cut their FY2026 earnings per share estimates for Ardelyx in a research note issued on Friday, November 1st. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of $0.06 for the year, down from their previous estimate of $0.08. Wedbush has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Ardelyx’s FY2027 earnings at $0.38 EPS and FY2028 earnings at $0.66 EPS.

Ardelyx (NASDAQ:ARDX) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. Ardelyx had a negative net margin of 28.82% and a negative return on equity of 46.86%. The firm had revenue of $73.20 million during the quarter, compared to analyst estimates of $55.03 million. During the same period in the previous year, the firm earned ($0.08) EPS. The business’s quarterly revenue was up 228.3% on a year-over-year basis.

ARDX has been the topic of a number of other reports. Citigroup raised their target price on Ardelyx from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Ardelyx in a report on Friday. Finally, StockNews.com raised Ardelyx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.67.

Ardelyx Stock Up 3.7 %

ARDX stock opened at $6.09 on Monday. Ardelyx has a one year low of $3.43 and a one year high of $10.13. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.99 and a current ratio of 4.21. The firm’s fifty day moving average is $6.07 and its 200 day moving average is $6.32. The firm has a market cap of $1.43 billion, a PE ratio of -20.30 and a beta of 0.92.

Insider Transactions at Ardelyx

In other Ardelyx news, insider David P. Rosenbaum sold 20,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $5.94, for a total value of $118,800.00. Following the transaction, the insider now owns 356,479 shares in the company, valued at approximately $2,117,485.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider David P. Rosenbaum sold 20,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $5.94, for a total transaction of $118,800.00. Following the completion of the sale, the insider now owns 356,479 shares of the company’s stock, valued at approximately $2,117,485.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Raab sold 32,225 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $5.86, for a total transaction of $188,838.50. Following the completion of the transaction, the chief executive officer now directly owns 1,227,009 shares in the company, valued at $7,190,272.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 212,126 shares of company stock valued at $1,298,963 over the last ninety days. Insiders own 5.90% of the company’s stock.

Institutional Trading of Ardelyx

Large investors have recently added to or reduced their stakes in the stock. Swiss National Bank boosted its position in shares of Ardelyx by 6.7% during the 1st quarter. Swiss National Bank now owns 458,300 shares of the biopharmaceutical company’s stock valued at $3,346,000 after acquiring an additional 28,900 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Ardelyx by 100.7% in the 1st quarter. Russell Investments Group Ltd. now owns 536,297 shares of the biopharmaceutical company’s stock valued at $3,915,000 after purchasing an additional 269,046 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Ardelyx by 8.9% in the 1st quarter. ProShare Advisors LLC now owns 57,729 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 4,735 shares during the period. Entropy Technologies LP acquired a new stake in shares of Ardelyx during the 1st quarter worth approximately $341,000. Finally, Vanguard Group Inc. raised its position in shares of Ardelyx by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 13,391,855 shares of the biopharmaceutical company’s stock valued at $97,761,000 after buying an additional 365,809 shares during the period. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.